SNDX Valuation

Syndax Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

13.730

-0.090(-0.650%)

Overview
Forecast
Valuation

SNDX Relative Valuation

SNDX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, SNDX is overvalued; if below, it's undervalued.

Historical Valuation

Syndax Pharmaceuticals Inc (SNDX) is now in the Fair zone, suggesting that its current forward PS ratio of 13.62 is considered Fairly compared with the five-year average of 439.11. The fair price of Syndax Pharmaceuticals Inc (SNDX) is between 8.03 to 25.17 according to relative valuation methord.

Relative Value

Fair Zone

8.03-25.17

Current Price：13.73

Fair

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

4.08

P/B

Median3y

3.51

Median5y

3.91

-23.12

FCF Yield

Median3y

-10.28

Median5y

-8.95

Competitors Valuation Multiple

The average P/S ratio for SNDX's competitors is 4.47, providing a benchmark for relative valuation. Syndax Pharmaceuticals Inc Corp (SNDX) exhibits a P/S ratio of 13.62, which is 204.94% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

SNDX.O

Syndax Pharmaceuticals Inc

13.62

Average P/S: 4.47

1.18B